跳转到内容

万替妥单抗

维基百科,自由的百科全书
万替妥单抗
单克隆抗体
种类?
目標卷曲受体
臨床資料
给药途径IV
ATC碼
  • 未分配
识别信息
CAS号1345009-45-1
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6322H9722N1674O1988S46
摩尔质量142,461.81 g·mol−1

万替妥单抗INN:Vantictumab)是一种人IgG2单克隆抗体,设计用于治疗癌症[1]

该药物由OncoMed英语OncoMed制药公司与拜耳合作开发。[2]OncoMed于2016年获得专利,预计将于2029年到期。[3]2017年4月,拜耳终止了对万替妥单抗的许可选择。[4]

它通过靶向癌细胞上的卷曲受体来抑制wnt信号传导。[5]

胰腺癌非小细胞肺癌乳腺癌的I期试验已经完成。2016年报告了三阴性乳腺癌1b期临床试验的结果,[5][6]2020年报告了胰腺癌的1b期临床试验结果。[7]

参考资料

[编辑]
  1. ^ Statement on a nonproprietary name adopted by the USAN Council (PDF). AMA. 28 Nov 2012. N12/155. 需註冊
  2. ^ OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance. 12 January 2015 [2024-03-01]. (原始内容存档于2024-03-01). 
  3. ^ Annual Report on Form 10-K. OncoMed Pharmaceuticals, Inc. (原始内容存档于13 January 2017). 
  4. ^ BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept. Reuters. 10 April 2017 [2024-03-01]. (原始内容存档于2021-05-18). 
  5. ^ 5.0 5.1 Finally, targeted therapies for triple-negative breast cancer. Medical Xpress. June 2016 [2024-03-01]. (原始内容存档于2024-01-08). 
  6. ^ Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment. November 2020, 184 (1): 53–62. PMC 7572714可免费查阅. PMID 32803633. doi:10.1007/s10549-020-05817-w. 
  7. ^ Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs. June 2020, 38 (3): 821–830. PMC 7211194可免费查阅. PMID 31338636. doi:10.1007/s10637-019-00824-1.